Protalix Biotherapeutics To Present Individual Participant Results From PK And PD Analysis Of Higher-Dose Cohorts Of Its Phase 1 Single Ascending Dose Study Of PRX-115, At ACR Convergence 2026

Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout

• The Company previously reported that higher single doses of PRX–115 lowered mean plasma uric acid for longer durations in participants with elevated plasma uric acid levels (ACR 2024)
• New individual patient data presented at ACR 2026 reinforce this finding and show the effect associated with PRX-115 plasma levels remaining measurable for up to 85 days
• The Company believes PRX-115 has best-in-class potential in uncontrolled gout, a high unmet need with top-line results from the Phase 2 RELEASE study expected in the second half of 2027

CARMIEL, Israel, Nov. 9, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced individual participant results from a pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the higher-dose cohorts of its Phase 1 single ascending dose study of PRX-115, a plant cell–expressed recombinant PEGylated uricase in development for uncontrolled gout. The Company is presenting the analysis in a poster at the American College of Rheumatology (ACR) Convergence 2026 taking place in Orlando, Florida from November 6-11, 2026.